Novel Role of IL-13 in Fibrosis Induced by Nonalcoholic Steatohepatitis and Its Amelioration by IL-13R-Directed Cytotoxin in a Rat Model
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Nonalcoholic steatohepatitis (NASH), the most common cause of chronic liver fibrosis, progresses to cirrhosis in up to 20% of patients. We report that hepatic stellate cells (HSC) in sinusoidal lesions of liver of patients with NASH express high levels of high-affinity IL-13R (IL-13Rα2), which is colocalized with smooth muscle actin, whereas fatty liver and normal liver specimens do not express IL-13Rα2. HSCs engineered to overexpress IL-13Rα2 respond to IL-13 and induce TGFB1 promoter activity and TGF-β1 production. We also developed NASH in rats by feeding a choline-deficient l-amino acid diet. These rats developed liver fibrosis as assessed by H&E staining, Masson’s trichrome and Sirius red staining, and hydroxyproline assays. Treatment of these rats with IL-13R-directed cytotoxin caused a substantial decline in fibrosis and liver enzymes without organ toxicity. These studies demonstrate that functional IL-13Rα2 are overexpressed in activated HSCs involved in NASH and that IL-13 cytotoxin ameliorates pathological features of NASH in rat liver, indicating a novel role of this cytotoxin in potential therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Iredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075
Beyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
Lee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.809 · Cited by 940 · cited 2×
“IL-13 seems to induce tissue fibrosis by stimulating and activating TGF- 1 (16).”
BackgroundIL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-β Independent
Kaviratne, M., Hesse, M., Leusink, M., Cheever, A. W., Davies, S. J., McKerrow, J. H., Wakefield, L. M., Letterio, J. J., & Wynn, T. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4020 · Cited by 370 · cited 1×
“However, in the context of schistosomiasis and helminth parasitic diseases, IL-13 can induce fibrosis in the absence of TGF- 1 and in this situation overexpressed IL-13R 2 acts as a soluble decoy receptor that decreases fibrosis (40).”
BackgroundShi, Z., Wakil, A. E., & Rockey, D. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10663 · Cited by 310
Kawaguchi, K., Sakaida, I., Tsuchiya, M., Omori, K., Takami, T., & Okita, K. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.038 · Cited by 160 · cited 1×
“To simulate these clinical features of NASH, we fed rats a CDAA diet to induce liver fibrosis as reported previously (30, 34).”
MethodMawdsley, J. E., Macey, M. G., Feakins, R. M., Langmead, L., & Rampton, D. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.05.017 · Cited by 143
Cited by
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
“…in chronic asthma 75 , IPF 76 , models of experimental lung fibrosis 77 , systemic sclerosis 78 , atopic dermatitis–induced skin fibrosis 79 , radiation-induced fibrosis 80 , fibrosis associated with ulcerative colitis 81 and liver fibrosis resulting from persistent infections and NASH 82,83 .”
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,160
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,058
Pulmonary fibrosis: pathogenesis, etiology and regulation
Wilson, M. S., & Wynn, T. A. (2009) · Mucosal Immunology · doi:10.1038/mi.2008.85 · Cited by 822
Host Responses in Tissue Repair and Fibrosis
Duffield, J. S., Lupher, M., Thannickal, V. J., & Wynn, T. A. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163930 · Cited by 624
Metadata
- Authors
- Shimamura, T., Fujisawa, T., Husain, S. R., Kioi, M., Nakajima, A., & Puri, R. K.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-10-01
- Volume
- 181
- Issue
- 7
- Pages
- 4656-4665
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2129234412
- Cited by
- 92
- References
- 9
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.